Fiche centre
MA-LEK Clinical Sp. Z o.o.
Katowice — Poland
Essais liés6clinical trials
VilleKatowicelocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04544436
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Interferon beta-1a | SEP | Phase 3 | NCT01247324 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Orelabrutinib | SEP | Phase 3 | NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |